The new drug-eluting stents (DES) equipped with ultra-thin struts are showing a lower risk of target lesion failure as a result of lower rates of acute myocardial infarction and similar rates of revascularization, according to this meta-analysis soon to be published in Circulation. Such a difference is evidenced at a 1-year follow-up when compared with<a href="https://solaci.org/en/2018/07/04/new-ultra-thin-strut-des-do-they-outperform-second-generation-des/" title="Read more" >...</a>
We are less than a month away from the most important interventional cardiology event in Latin America. Consequently, we have started to share information on some of the most appealing sessions that you will be able to enjoy in Mexico City from August 1st to 3rd, 2018. On that vein, we are pleased to communicate<a href="https://solaci.org/en/2018/07/03/over-10-keynote-conferences-confirmed-at-solaci-socime-2018-congress/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR), both isolated or associated with other left valve diseases, has been associated with higher rates of heart failure hospitalization and of cardiovascular death. Recent studies in elderly high-risk patients who underwent percutaneous treatment of left valve disease have shown the presence of TR to be associated with<a href="https://solaci.org/en/2018/07/02/tricuspid-regurgitation-mitraclip-improves-survival/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic stenosis with cardiac failure or cardiogenic shock involves high mortality risk at short term. Surgery in these conditions is often unsafe, which leaves us with valvuloplasty, but only as a bridge to some other procedure, seeing as it is effective only for a short time. Few studies have looked into patients undergoing<a href="https://solaci.org/en/2018/06/20/urgent-emergent-tavr-a-valid-option/" title="Read more" >...</a>
The use of functional assessment of coronary stenosis (following the class IA recommendation in both American and European guidelines) is below 50% in daily clinical practice. Truth be told, most operators continue having blind faith in angiography. The inclusion of coronary physiology in the decision-making process has spread widely across countries, sites, and operators. The ERIS<a href="https://solaci.org/en/2018/06/18/real-life-functional-assessment-of-coronary-stenosis-we-are-yet-to-convert-to-it/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Stroke is one of the most undesirable complications we can face and, regarding transcatheter aortic valve replacement (TAVR), major studies presented have rates of stroke of about 4%. In others, rates have been slightly higher. This meta-analysis included 5 randomized studies between 2011 and 2017: PARTNER, CoreVALVE, NOTION, PARTNER 2, and SURTAVI.<a href="https://solaci.org/en/2018/06/12/are-the-rates-of-stroke-similar-in-tavr-and-surgery/" title="Read more" >...</a>
A new edition of EuroPCR has come and gone. Now is the time to make a balance and review the main presentations at one of the most important European congresses on cardiovascular interventions. Thus, we have selected the six most relevant studies presented at the event. In our opinion, you cannot afford to miss them!<a href="https://solaci.org/en/2018/06/07/europcr-2018-highlights-the-best-of-a-congress-that-left-plenty-of-news/" title="Read more" >...</a>
Intentional leaflet laceration before mounting the prosthesis on the release system, so as to reduce the risk of acute coronary occlusion, seems a desperate maneuver to force transcatheter aortic valve replacement (TAVR). Unfortunately, we will always encounter patients without other real choice; in those cases, creativity may start as compassionate treatment and then be upgraded<a href="https://solaci.org/en/2018/06/04/leaflet-laceration-an-extreme-measure-to-avoid-coronary-occlusion-after-tavr/" title="Read more" >...</a>
First generation TAVR procedures performed on patients with bicuspid aortic valve stenosis have rendered suboptimal outcomes. In addition, studies on new generation devices, such as the SAPIEN 3, have systematically excluded these patients from their protocols. Therefore, we are missing information about TAVR on bicuspid aortic valve stenosis patients. This study compared SAPIEN 3 TAVR<a href="https://solaci.org/en/2018/05/30/europcr-2018-sapien-3-in-bicuspids/" title="Read more" >...</a>
The rate of cerebrovascular events in TAVR hovers about 4% in most of the current studies, regardless the center, the operator or the prosthetic valve. At present, no scores can adequately predict which patients run the highest risk of stroke during TAVR, and the routine use of cerebral protection devices remains controversial. The SENTINEL study<a href="https://solaci.org/en/2018/05/30/europcr-2018-sentinel-anatomical-predictors-of-stroke-during-tavr/" title="Read more" >...</a>